Global gRNA Market Insights Forecasts to 2033

• The Global gRNA Market Size was Valued at USD 487.06 Million in 2023
• The Market Size is Growing at a CAGR of 18.59% from 2023 to 2033
• The Worldwide gRNA Market  Size is Expected to Reach USD 2679.86 Million by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The gRNA Market Size is Anticipated to Exceed USD 2679.86 Million by 2033, Growing at a CAGR of 18.59% from 2023 to 2033.

Market Overview

Guide RNA (gRNA) a particular RNA sequence that identifies the target DNA's area of interest. It attaches itself to the Cas9 protein and guides it to the intended location to transmit the change. In laboratories, recombinant gRNA is used in conjunction with other reagents to carry out a variety of assays such as multiplex PCR, classic PCR, complete genome sequencing cloning procedures cell line growth, primers, and recombinant plasmid DNA, in addition to mismatch assays for mutations, DNA modification, and gene expression research. gRNA is used by scientists and researchers to precisely target and change genes, leading to ground-breaking developments in biotechnology, agriculture, and medicine. Its adaptability, precision, and effectiveness have increased demand for it by offering hope for novel agricultural techniques, the understanding of basic biological processes, and possible treatments for hereditary illnesses. These benefits help the expansion of the gRNA market. Increasing R&D activity in proteomics and genomics serves as significant market drivers.

Governments and commercial entities are investing extensively in proteomics and genomics research, resulting in an increasing the demand for gRNA technologies. For example, in April 2021, the US government committed USD 1.7 billion in financing to develop and enhance genome sequencing technology.

Report Coverage

This research report categorizes the market for the gRNA market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the gRNA market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the gRNA market.

Driving Factors

The gRNA market is propelled by several factors including as gRNA requirement has increased significantly as a result of CRISPR-Cas9's extensive use in gene editing. The gRNA market is growing due to government and private investments in biotechnology and genomic research. There are a number of important variables that have contributed to the gRNA (guide RNA) market's explosive expansion. The increasing need for precision medicine has promoted the use of advanced gene editing instruments, with specific genomic modifications made possible in large part by gRNA.

Restraining Factors

The gRNA has specific risk factors or drawbacks, such as mismatches between the gRNA and the target site, which, depending on their locations and the number of mismatches, may cause off-target effects. Because the specificity and activity may vary, it could be essential to design multiple gRNA for each gene of interest.

Market Segmentation

The gRNA market share is classified into product & services, gRNA type, application, and end-use.

• The products segment is expected to grow at the highest CAGR during the estimated period.

Based on the product & services, the gRNA market is divided into products and custom gRNA synthesis services. Among these, the products segment is expected to grow at the highest CAGR during the estimated period. This dominance is due to researchers appreciating these tools because they provide great specificity, efficiency, and precision in gene editing. The market provides a wide range of services along with products, including gRNA design, synthesis, and distribution. The primary driver of this segment's popularity is these products' high purity and widespread availability.

• The research-use segment accounted for the largest revenue share over the projection period.

Based on the gRNA type, the gRNA market is divided into research-use and GMP-grade. Among these, the research-use segment accounted for the largest revenue share over the projection period. Research-grade gRNA is required for a wide range of research activities carried out at different research facilities. The market is anticipated to continue to dominate due to the growing use of gRNA in clinical research. Additionally, the increasing usage of the gene-editing tool CRISPR/Cas9 is increasing demand for gRNA in the research market.

• The genome engineering segment dominates the market with the highest market share through the projection period.

On the basis of application, the gRNA market is divided by genome engineering, disease model studies, functional genomics, epigenetics, and others. Among these, the genome engineering segment dominates the market with the highest market share through the projection period. The revolutionary influence of gRNA across various industries makes genome engineering a profitable technology. Genetic changes have been transformed by the accuracy and adaptability of gRNA in CRISPR-based editing, opening up enormous possibilities in biotechnology, agriculture, and human health.

• The pharmaceutical & biotechnology companies segment holds the largest market share through the forecast period.

Based on the end-use, the gRNA market is divided into pharmaceutical & biotechnology companies, academic research institutes, and CMOs & CROs. Among these, the pharmaceutical & biotechnology companies segment holds the largest market share through the forecast period. The development of adapted medicines is fueled by the use of gRNA in precision medicine, which is being adopted by pharmaceutical and biotech businesses. Gene-reactors (biotech) use gRNA to optimize bio-production processes, including cell line expansion for bio-therapeutic production.

Regional Segment Analysis of the GRNA Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the gRNA market over the predicted timeframe.

North America is anticipated to hold the largest share of the gRNA market over the predicted timeframe. The leading position of the area in the gRNA industry can be ascribed to various causes, including the noteworthy increase in research and development investments made by these entities to pioneer cutting-edge and creative products, and the large presence of important players. For example, Thermo Fisher & Pfizer, Inc. partnered in May 2023 to increase cancer patients' access to NGS-based testing. The focus of this is breast and lung cancer, two important and common tumors in the world.

Asia Pacific is expected to grow at the fastest CAGR growth in the gRNA market during the forecast period. The growth is primarily attributed to the sizeable target population, rapid adoption of different technologies, the rise of multiple startups, the continuous market expansion of healthcare infrastructure, and the significant amount of unmet clinical needs. To encourage the expansion of the biotech sector, the Chinese government has implemented several initiatives.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the gRNA market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Market Players

• Thermo Fisher Scientific Inc.
• CRISPER QC
• Synthego
• Merck KGaA
• Jena Bioscience GmbH
• Agilent Technologies Inc.
• Takara Bio Inc.
• Mirus Bio LLC
• Integrated DNA Technologies, Inc.
• Mammoth Biosciences, Inc.
• Horizon Discovery Ltd.
• System Biosciences, LLC.
• Synbio Technologies
• GENEWIZ (Azenta Life Sciences)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2024, BioAro, a leader in genomic research and technology, officially introduced "PanOmiQ," the world's fastest multi-genomic analysis service. It contributes to reducing health hazards.

• In April 2024, The first open-source AI-generated gene editor was released by Profluent, an AI-first protein creation organization, as part of their OpenCRISPRTM effort. Profluent utilized AI to create fully customisable gene editors from scratch, marking the first successful instance of precision editing the human genome. Using Profluent's large language models (LLMs), an AI is used to develop the gene editor OpenCRISPR-1, which comprises of a guide RNA and a Cas9-like protein.

• In May 2023, PerkinElmer, Inc. and Horizon Discovery Group plc are excited to announce that they have achieved a contract on the conditions of a recommended all cash offer, under which PerkinElmer plans to buy Horizon for approximately $383 million.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the gRNA market based on the below-mentioned segments: 

Global gRNA Market, By Product & Services

• Products
• Custom gRNA Synthesis Services

Global gRNA Market, By gRNA Type

• Research-Use
• GMP-grade

Global gRNA Market, By Application

• Genome Engineering
• Disease Model Studies
• Functional Genomics
• Epigenetics
• Others

Global gRNA Market, By End-use

• Pharmaceutical & Biotechnology Companies
• Academic Research Institutes
• CMOs & CROs

Global gRNA Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa